(MENAFN - ProactiveInvestors) <\/p>\n
Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis. <\/p>\n
The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015. <\/p>\n
Adding interest the company highlighted the benefit of using adipose or fat tissue over other tissue types by demonstrating the capacity to produce millions of therapeutic doses of Progenza from a single donor. <\/p>\n
The production of commercial quantities of stem cells from a single donor is critical to maximise dose-to-dose consistency chief executive officer John Martin said. <\/p>\n
This scale of production will minimise clinical trial and regulatory risks while reducing the cost of the final product. <\/p>\n
One of the key advantages for manufacturing Progenza at industrial scale is that it uses stem cells sourced from adipose or fat tissue. <\/p>\n
Adipose tissue is readily available from donors in large quantities and has significantly higher stem cells per gram of tissue than other tissue sources such as bone marrow or cord tissue. <\/p>\n
Also adipose derived stem cells show greater capacity for expansion than stem cells from other tissue types. <\/p>\n
Progenza adipose derived stem cells are adult stem cells they are not genetically modified like induced pluripotent stem cells (iPSC). <\/p>\n
<\/p>\n
Read the original here: <\/p>\n
Regeneus hits key stem cell manufacturing milestone<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" (MENAFN - ProactiveInvestors) Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis. The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015. Continue reading